CN104807935B - 一种盐酸莫西沙星中间体及其对映异构体的分离检测方法 - Google Patents
一种盐酸莫西沙星中间体及其对映异构体的分离检测方法 Download PDFInfo
- Publication number
- CN104807935B CN104807935B CN201510219060.7A CN201510219060A CN104807935B CN 104807935 B CN104807935 B CN 104807935B CN 201510219060 A CN201510219060 A CN 201510219060A CN 104807935 B CN104807935 B CN 104807935B
- Authority
- CN
- China
- Prior art keywords
- enantiomer
- detection method
- moxifloxacin hydrochloride
- normal hexane
- reference substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 title claims abstract description 53
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 13
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 claims abstract description 41
- 238000001514 detection method Methods 0.000 claims abstract description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 9
- QKGYJVXSKCDGOK-UHFFFAOYSA-N hexane;propan-2-ol Chemical compound CC(C)O.CCCCCC QKGYJVXSKCDGOK-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000945 filler Substances 0.000 claims abstract description 5
- SBTVLCPCSXMWIQ-UHFFFAOYSA-N (3,5-dimethylphenyl) carbamate Chemical compound CC1=CC(C)=CC(OC(N)=O)=C1 SBTVLCPCSXMWIQ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000012360 testing method Methods 0.000 claims description 55
- 239000013558 reference substance Substances 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 9
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 claims description 5
- 238000010812 external standard method Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000005259 measurement Methods 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 3
- 238000004305 normal phase HPLC Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 48
- 239000012071 phase Substances 0.000 description 20
- 230000014759 maintenance of location Effects 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 4
- 229960003702 moxifloxacin Drugs 0.000 description 4
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- -1 boron ester Chemical class 0.000 description 2
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FGBGEKHVEJJJLT-LLVKDONJSA-N 1-cyclopropyl-7-[(3r)-3-ethylpyrrolidin-1-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid Chemical group C1[C@H](CC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC FGBGEKHVEJJJLT-LLVKDONJSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
Description
峰# | 保留时间 | 面积 | 高度 | 面积% | 分离度 |
1 | 20.089 | 85263 | 764 | 0.180 | 0.000 |
2 | 24.285 | 47293478 | 180187 | 99.820 | 1.798 |
总计 | 47378741 | 180951 | 100.000 |
峰# | 保留时间 | 面积 | 高度 | 面积% | 分离度 |
1 | 20.522 | 3760756 | 28839 | 14.775 | 0.000 |
2 | 25.349 | 21692297 | 92296 | 85.225 | 1.907 |
总计 | 25453053 | 121135 | 100.000 |
编号 | 1 | 2 | 3 | 4 | 5 | 6 | RSD |
峰面积 | 868240 | 867529 | 864964 | 857917 | 866972 | 860854 | 0.48% |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510219060.7A CN104807935B (zh) | 2015-04-30 | 2015-04-30 | 一种盐酸莫西沙星中间体及其对映异构体的分离检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510219060.7A CN104807935B (zh) | 2015-04-30 | 2015-04-30 | 一种盐酸莫西沙星中间体及其对映异构体的分离检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104807935A CN104807935A (zh) | 2015-07-29 |
CN104807935B true CN104807935B (zh) | 2016-06-08 |
Family
ID=53692943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510219060.7A Active CN104807935B (zh) | 2015-04-30 | 2015-04-30 | 一种盐酸莫西沙星中间体及其对映异构体的分离检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104807935B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111208216B (zh) * | 2018-11-21 | 2023-03-14 | 浙江医药股份有限公司新昌制药厂 | 奈诺沙星或其盐的光学异构体的分离方法 |
CN113125587B (zh) * | 2019-12-30 | 2022-05-24 | 成都百裕制药股份有限公司 | 一种托法替尼中间体及其对映异构体的检测方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1651630A1 (en) * | 2003-08-05 | 2006-05-03 | Matrix Laboratories Ltd | An improved process for the preparation of moxifloxacin hydrochloride |
CN102250088A (zh) * | 2011-05-06 | 2011-11-23 | 南京大海药物研究有限公司 | 一种n-甲基化的8-甲氧基喹诺酮甲酸类化合物的盐、制备方法及应用 |
ITTO20110705A1 (it) * | 2011-07-29 | 2013-01-30 | Italiana Sint Spa | Procedimento di preparazione della moxifloxacina cloridrato e relativi intermedi |
CN103172629B (zh) * | 2011-12-22 | 2016-06-22 | 天津康鸿医药科技发展有限公司 | 一种高纯度盐酸莫西沙星的合成方法 |
CN103185757B (zh) * | 2011-12-28 | 2015-03-25 | 天津康鸿医药科技发展有限公司 | 一种莫西沙星(r,r)-异构体的检测方法及其应用 |
CN103543230B (zh) * | 2012-07-09 | 2015-09-30 | 北大方正集团有限公司 | 一种盐酸莫西沙星及其对映异构体的分离测定方法 |
CN103860520A (zh) * | 2012-12-14 | 2014-06-18 | 南京长澳医药科技有限公司 | 一种莫西沙星胶囊剂及其制备方法 |
CN103869033B (zh) * | 2012-12-14 | 2016-10-05 | 南京长澳医药科技有限公司 | 一种液相色谱法分离测定盐酸莫西沙星及其杂质的方法 |
CN103396416B (zh) * | 2013-07-17 | 2015-06-17 | 南京优科生物医药研究有限公司 | 一种莫西沙星杂质f的制备方法 |
-
2015
- 2015-04-30 CN CN201510219060.7A patent/CN104807935B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104807935A (zh) | 2015-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104062375B (zh) | 一种同时检测药品及其对映异构体杂质的方法 | |
CN105699524B (zh) | 一种替格瑞洛中异构体杂质含量的检测方法 | |
CN105424822B (zh) | 检测替格瑞洛中(1r,2s)‑2‑(3,4‑二氟苯基)环丙胺的方法 | |
CN106841413A (zh) | 一种替格瑞洛对映异构体、非对映异构体的分离检测方法 | |
CN105510482B (zh) | 一种替格瑞洛原料中异构体杂质含量的检测方法 | |
CN103926340B (zh) | 一种化妆品中硝基呋喃类抗生素的测定方法 | |
CN104792891B (zh) | 一种r构型利伐沙班中间体的检测方法 | |
CN104807935B (zh) | 一种盐酸莫西沙星中间体及其对映异构体的分离检测方法 | |
CN105004803B (zh) | 一种分离测定托伐普坦中多个杂质的液相色谱方法 | |
Hewala | High-performance liquid chromatographic and derivative difference spectrophotometric methods for the determination of acetaminophen and its degradation product in aged pharmaceutical formulations | |
CN103487520B (zh) | 甲磺酸帕珠沙星注射液右旋异构体的手性固定相检测法 | |
CN103487521A (zh) | 甲磺酸帕珠沙星注射液右旋异构体的检测方法 | |
CN102226790A (zh) | 高效液相色谱法测定庆大霉素普鲁卡因维b12颗粒中盐酸普鲁卡因含量的方法 | |
CN114965754B (zh) | 对乙酰氨基酚片中有关物质及抑菌剂的检测方法 | |
CN104597157B (zh) | 一种脂溶性铂配合物及其制剂有关物质的测定方法 | |
CN110118836A (zh) | 高效液相色谱法测定利伐沙班中遗传毒性杂质的方法 | |
CN107271600B (zh) | 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法 | |
CN107328880B (zh) | 一种反相色谱分离盐酸帕洛诺司琼注射液有关物质的方法 | |
CN107219312B (zh) | 一种检测磷酸特地唑胺异构体杂质的方法 | |
CN104977368A (zh) | 一种4-[(4-氟苯基亚胺)甲基]-苯酚的有关物质检测方法及其应用 | |
CN104807934A (zh) | 异吲哚二酮类化合物的正相高效液相色谱检测方法 | |
CN105628824A (zh) | 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法 | |
CN104829660A (zh) | 一种克林霉素磷酸酯的同分异构体 | |
CN106855542B (zh) | 高效液相色谱检测美他多辛有关物质的方法 | |
CN106483205A (zh) | 一种采用高效液相色谱法检测药用辅料胭脂红含量的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 610000 Wenjiang, Sichuan Province, Chengdu Strait science and Technology Development Zone Development Zone Patentee after: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. Address before: 611130, Sichuan Wenjiang District, Chengdu Province, Chengdu Strait science and technology production area development zone Patentee before: CHENGDU BAIYU TECHNOLOGY PHARMACY Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A method for separation and detection of moxifloxacin hydrochloride intermediate and its enantiomer Effective date of registration: 20230511 Granted publication date: 20160608 Pledgee: Chengdu small business financing Company Limited by Guarantee Pledgor: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980040353 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20160608 Pledgee: Chengdu small business financing Company Limited by Guarantee Pledgor: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980040353 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A separation and detection method for intermediate and enantiomer of moxifloxacin hydrochloride Granted publication date: 20160608 Pledgee: Chengdu small business financing Company Limited by Guarantee Pledgor: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980018187 |